Indian drugmakers will be ‘essential’ in Covid-19 therapy production

The UN-backed public health body said India’s generic drug makers would have an “essential” role to bring Kovid-19 therapeutics to low and middle-income countries.

The Medicines Patent Pool’s executive director, Charles Gore, who works to improve drug access in developing countries, told CNBC on Wednesday that it is already working to accelerate the treatment of coronavirus. The manufacturers are based in the South Asian country.

Covid-19 therapy production
Covid-19 therapy production – Sajjad Hussain | AFP | Getty Images

This number only increases when major pharmaceutical manufacturers license their treatments for mass production.

Whites may have a really important role for Indian generic drug makers, Gore said, to combat coronavirus that has infected more than 56.1 million people so far – 8.9 million in India alone.

In this photo taken on September 2, 2020, a worker shows syringes at the Hindustan Syringe factory in Faridabad.


India is home to the world’s largest generic drugs market and has already proved to be important in delivering low-cost drugs, especially to poor countries.

The same would be true for this epidemic, Gore said, especially if countries are forced to bear the costs of treatment and vaccines.

“It will be especially important if countries themselves have to pay for these drugs. It would be necessary, really,” he said.

To think that vaccines are going to completely resolve this in the next two years is overly optimistic. We will still badly need medical …

Charles gore

Executive Director, Medicines Patent Pool

Gore’s organization is currently working with major drug developers to obtain licenses for its treatment, so that generic drug makers, such as those in India, are “cheaper” but still “high quality” for poor countries. Version.

Although some treatments have shown promise, none are ready yet, Gore said, adding that he estimates further data within the next three months.

Gore said he was shocked by the positive news from vaccine developers this week. However, he said the roll out would not be quick, and therapeutics would still be important.

“Thinking that the vaccines are going to completely resolve this in the next two years is overly optimistic. We will still need medicines for people suffering clinically badly,” he said.

Related Posts